Administrative Core
Administrative Core
批准号:
10017011
负责人:
KEVIN M FLANIGAN
金额:
$13.84万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-14 至 2022-08-31
关键词:
Basic ScienceClinicClinicalDevelopmentDiseaseDoctor of PhilosophyDuchenne muscular dystrophyDystrophinEnzymesEvaluationFacioscapulohumeral Muscular DystrophyFundingGenesGoalsInnovative TherapyKnowledgeMerosin-Deficient Congenital Muscular Dystrophy 1AMissionMuscular DystrophiesMyopathyNational Institute of Arthritis and Musculoskeletal and Skin DiseasesOhioPathogenesisPatientsPediatric HospitalsPrincipal InvestigatorProcessQuality of lifeReportingResearchResearch InstituteResourcesRoleSkeletal MuscleTranslatingTranslational ResearchTranslationsUniversitiesbench to bedsideboyseffective therapygene therapyglycosylationhuman diseaseimprovedinterestmuscle formnovel strategiesoverexpressionprogramsprotein expressionsynergismtherapeutic developmenttherapy developmenttype 1a limb girdle muscular dystrophy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Administrative Core:
Abstract
The Center for Gene Therapy at The Research Institute of Nationwide Children's Hospital
(RINCH) has a dedicated translational program that targets the muscular dystrophies, with a
particular longstanding interest in developing meaningful therapies for the most common forms,
including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy
(FSHD). Our Center's goals include unraveling disease pathogenesis and developing new
treatment paradigms that can be translated from the bench to the bedside, and under this
CORT proposal we seek to accelerate this translational process.
Project 1 (PI, Paul Martin, PhD) seeks extend a therapy now entering trials in DMD to other
forms of muscular dystrophy by applying the overexpression of Galgt2, an enzyme that alters
skeletal muscle glycosylation, to boost the expression of proteins that ameliorate disease.
Project 2 (PI, Scott Harper, PhD) explores novel approaches to modulating the expression of
the DUX4 gene to treat the relatively common and debilitating FSHD. Project 3 (PI, Kevin
Flanigan, MD) seeks to rapidly translate a newly discovered mechanism for dystrophin
translational control into meaningful therapy for boys with DMD.
The role of the Administrative Core will be to (1) facilitate scientific integration among these
three projects; (2) oversee the budgetary and reporting aspects of the CORT; (3) develop and
organize the Advisory Board's efforts; and (4) cultivate or identify pilot and feasibility projects for
submission to the NIAMS for funding consideration. On a broader level, the Administrative Core
will be responsible for maximizing the synergy between this CORT and other existing
translational efforts at RINCH, and at the Ohio State University.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes
-
批准号:10660396
-
项目类别:
-
资助金额:$45.44万
-
财政年份:2023
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:9767664
-
项目类别:
-
资助金额:$144.31万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Project 3: Use of an IRES-driven N-truncated dystrophin isoform as a clinical therapy for 5 mutations in the dystrophinopathies
-
批准号:10017028
-
项目类别:
-
资助金额:$29.96万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:10016996
-
项目类别:
-
资助金额:$141.75万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:9353717
-
项目类别:
-
资助金额:$148.7万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Center of Research Translation in Muscular Dystrophy Therapeutic Development
-
批准号:9194559
-
项目类别:
-
资助金额:$150.0万
-
财政年份:2016
-
负责人:KEVIN M FLANIGAN
-
依托单位:
First-in-Human rAAVrh74.MCK.GALGT2 DMD Clinical Trial
-
批准号:8884256
-
项目类别:
-
资助金额:$26.31万
-
财政年份:2015
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:8847815
-
项目类别:
-
资助金额:$82.54万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:9057628
-
项目类别:
-
资助金额:$77.48万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:9320661
-
项目类别:
-
资助金额:$77.48万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:10522759
-
项目类别:
-
资助金额:$94.62万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:10682505
-
项目类别:
-
资助金额:$93.22万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Genetic modifiers of Duchenne Muscular Dystrophy
-
批准号:8761968
-
项目类别:
-
资助金额:$98.77万
-
财政年份:2014
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8267606
-
项目类别:
-
资助金额:$87.96万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8733204
-
项目类别:
-
资助金额:$120.48万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIIB by Systemic Gene Delivery
-
批准号:8701736
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8500478
-
项目类别:
-
资助金额:$120.72万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
Treating the CNS and Somatic Diseases of MPS IIB Systemic Gene Delivery
-
批准号:8109732
-
项目类别:
-
资助金额:$89.0万
-
财政年份:2011
-
负责人:KEVIN M FLANIGAN
-
依托单位:
CLINICAL TRIAL: NONSENSE-MUTATION-MEDIATED DUCHENNE MUSCULAR DYSTROPHY
-
批准号:7718520
-
项目类别:
-
资助金额:$2.31万
-
财政年份:2008
-
负责人:KEVIN M FLANIGAN
-
依托单位:
STUDY OF INHERITED NEUROLOGICAL DISEASES
-
批准号:7718503
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2008
-
负责人:KEVIN M FLANIGAN
-
依托单位:
海外基金